This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Acute myelogenous leukemia (AML)

Hemopoietic cell kinase (HCK)

SAR and mouse studies suggest HCK inhibitors could be useful for treating AML. SAR studies identified an HCK inhibitor with higher specificity for HCK than for related kinases. In primary cultured AML cells, the compound inhibited tumor growth with nanomolar IC50 values. In a mouse xenograft model for human AML, the compound prevented tumor growth in bone and spleen. Next steps include preclinical toxicology, pharmacokinetic and pharmacodynamic studies.

SciBX 6(19); doi:10.1038/scibx.2013.458
Published online May 16, 2013

Patent pending; available for licensing

Saito, Y. et al. Sci. Transl. Med.; published online April 17, 2013;
doi:10.1126/scitranslmed.3004387
Contact: Fumihiko Ishikawa, RIKEN Research Center for Allergy and Immunology, Yokohama, Japan
e-mail:
f_ishika@rcai.riken.jp